411.2 ð åèçïŒé«åž«åè / PGY OSCEïŒ
411.2.0.1 ð Cram Sheet
411.2.0.1.1 ð¥ é« yield 10
- CV #1 mortality in women
- MI atypical: fatigue, jaw, back pain
- SCAD: 90% women, peri-partum, FMD
- Takotsubo: 90% postmenopausal women
- Lung CA #1 cancer death in women now (surpass breast)
- HPV vaccine †45 yo
- PMDD: SSRI luteal or continuous
- Postpartum depression 10-15%: zuranolone oral 22E
- Autoimmune 80% women
- Osteoporosis 2-3x men
411.2.0.1.2 ð¢ å¿ è
| é ç® | æžå |
|---|---|
| Heart disease women rank | #1 mortality |
| Lung CA in women | #1 cancer death |
| Breast CA lifetime | 1/8 (1/13 Taiwan) |
| PPD prevalence | 10-15% |
| PPD risk factors | Prior depression, family Hx |
| SLE F:M | 9:1 |
| RA F:M | 3:1 |
| MS F:M | 3:1 |
| Hashimoto F:M | 7:1 |
| Osteoporosis F:M | 2-3x |
| Postpartum thyroiditis | 5-10% |
| Postpartum hemorrhage Sheehan | rare |
411.2.0.2 â é« yield
411.2.0.2.1 å¥³æ§ CV Specifics
- HFpEF more common in women
- Microvascular angina (INOCA)
- SCAD (peri-partum, FMD)
- Takotsubo
- Anatomy: smaller coronary, more spasm
411.2.0.2.2 Postpartum Depression Drugs
- Sertraline (preferred breastfeeding)
- Paroxetine (OK breastfeeding)
- Brexanolone IV (FDA 2019)
- Zuranolone oral (FDA 2023, 22E)
- Psychotherapy + ECT (severe)
411.2.0.3 ð¯ èªææª¢æž¬
- Heart disease women rank? â #1 mortality
- Lung cancer women rank? â #1 cancer death (surpass breast)
- SCAD demographics? â 90% women, peri-partum, FMD
- Takotsubo demographics? â 90% postmenopausal
- PMDD definition? â ⥠5 symptoms luteal + functional
- PMDD treatment? â SSRI + COC
- PPD prevalence? â 10-15%
- Postpartum depression drugs? â Sertraline, paroxetine, brexanolone IV, zuranolone oral (22E)
- Postpartum thyroiditis %? â 5-10%
- SLE F:M ratio? â 9:1
- Osteoporosis F:M? â 2-3x
- HPV vaccine age? â †45 yo
- BRCA surveillance? â MRI + mammography from 25-30
- Mens MI vs Women MI? â Women atypical (fatigue, jaw, back)
- Lynch surveillance? â Colonoscopy q1-2y from 20-25
â ïž AI èçš¿ã